MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 68,289 Shares

MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos sold 68,289 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the transaction, the chief executive officer owned 2,774,893 shares of the company’s stock, valued at $55,553,357.86. This trade represents a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Da Silva Jorge Santos also recently made the following trade(s):

• On Thursday, July 9th, Da Silva Jorge Santos sold 33,936 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $20.01, for a total transaction of $679,059.36.
• On Wednesday, July 1st, Da Silva Jorge Santos sold 47,775 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $20.03, for a total transaction of $956,933.25.

MoonLake Immunotherapeutics Stock Up 0.2%

MLTX stock opened at $20.41 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 8.60 and a quick ratio of 8.60. The company’s 50 day simple moving average is $18.68 and its 200-day simple moving average is $17.30. MoonLake Immunotherapeutics has a 12 month low of $5.95 and a 12 month high of $62.75. The firm has a market capitalization of $1.50 billion, a PE ratio of -5.27 and a beta of 1.04.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.07). Equities analysts expect that MoonLake Immunotherapeutics will post -3.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MLTX. Kestra Advisory Services LLC purchased a new position in MoonLake Immunotherapeutics during the fourth quarter worth about $26,000. EverSource Wealth Advisors LLC boosted its stake in MoonLake Immunotherapeutics by 221.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company’s stock worth $53,000 after buying an additional 1,974 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in MoonLake Immunotherapeutics in the 2nd quarter valued at about $58,000. Russell Investments Group Ltd. grew its holdings in MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after buying an additional 1,069 shares during the period. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of MoonLake Immunotherapeutics during the 4th quarter valued at about $47,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Monday, June 8th. BTIG Research reiterated a “buy” rating and set a $30.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 12th. Needham & Company LLC upped their target price on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Finally, Rothschild & Co Redburn raised shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $12.00 to $40.00 in a research note on Thursday, March 19th. Ten analysts have rated the stock with a Buy rating, four have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $24.21.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.